Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of darotropium bromide in COPD
NCT00676052Phase 2Completed
- Sponsor
- GSK
- Start
- May 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of darotropium bromide in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started May 2008; status: completed.
02
Drugs
darotropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00676052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00676052.